At a glance
ClinicalIndex Comparison RecordN/ACompleted· 15 enrolled
Drug / intervention
Immune Globulin Subcutaneous (Human)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Study of Subcutaneous Immunoglobulin as Chronic Treatment for Patients With Chronic Inflammatory Demyelinating Polyneuropathy
In Brief
A clinical study evaluating Immune Globulin Subcutaneous (Human) for Chronic Inflammatory Demyelinating Polyneuropathy. Completed, enrolled 15 participants across 1 site.
Detailed Summary
The investigators are using self administered subcutaneous immunoglobulin (SCIG) in patients with CIDP who require Intravenous immunoglobulin (IVIG). Safety, efficacy, and patient satisfaction will be examined.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsCSL Behring
Timeline
N/ACompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartSep 2014
First PostedJun 2015
Primary CompletionMar 2018
Study CompletionMay 2021
TodayJul 2026
First PostedJun 8, 2015
Enrollment StartSep 1, 2014
Primary CompletionMar 1, 2018
Study CompletionMay 1, 2021
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 11.1 years ago
Interventions
Immune Globulin Subcutaneous (Human)drug
Patients who have CIDP and are on IVIG will be allowed in the study to try subcutaneous immune Globulin (SCIG) as part of an open label study.